Evidence map›Paper›PMID 40092521›Full record

ArticleIJTLD open2025

Treatment outcomes of pulmonary TB in adults in Indonesia.

R I Sugiyono, A M Naysilla, N H Susanto, D Handayani, E Burhan, A Karuniawati, T Kusmiati, B H Wibisono, B S Riyanto, I G K Sajinadiyasa and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

R I SugiyonoIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
A M NaysillaIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
N H SusantoIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
D HandayaniDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia.
E BurhanDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia.
A KaruniawatiDepartment of Microbiology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
T KusmiatiDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia.
B H WibisonoDivision Pulmonology and Critical Care, Department of Internal Medicine, Kariadi Hospital, Semarang, Indonesia.
B S RiyantoDivision of Pulmonology, Department of Internal Medicine Sardjito Hospital, Yogyakarta, Indonesia.
I G K SajinadiyasaPulmonology Division of Internal Medicine Department, Prof. Dr. I.G.N.G. Ngoerah Hospital, Denpasar, Indonesia.
I DjaharuddinDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Hasanuddin University, Wahidin Sudirohusodo Hospital, Makassar, Indonesia.
B Y M SinagaDepartment of Pulmonology and Respiratory Medicine, Adam Malik Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
R D DewantaraIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
M KaryanaIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
H KosasihIndonesia Research Partnership on Infectious Diseases (INA-RESPOND), Jakarta, Indonesia.
C J LiangBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
R RidzonCollaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
A T NealCollaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
R Y ChenCollaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAchieving the goal of Ending TB requires a treatment success rate of ≥90%, a challenging target for Indonesia. To understand outcomes and associated factors for unfavourable outcomes, we analysed prospective multicentre study data from 2017 to 2020 involving drug-susceptible TB (DS-TB) and multidrug-resistant TB (MDR-TB) treatment adult patients.

methodsThis study focused on bacteriologically confirmed participants based on Xpert MTB/RIF or culture results. We analysed participants with available treatment outcomes - cured, completed, failed, dead, and lost to follow-up (LTFU) - excluding withdrawn or transferred. Univariable and multivariable logistic regression analyses identified factors associated with unfavourable outcomes.

resultsAmong 328 bacteriologically confirmed participants with available outcomes, the overall treatment success was 72.3% (DS-TB: 81.6% and MDR-TB: 60.1%). Unfavourable outcomes were 27.7%, with 3.6% failures, 9.5% deaths, and 14.6% LTFUs. Associated factors for unfavourable outcomes included age ≥50 years (aOR 2.54, 95% CI 1.11-5.95;

conclusionStrategies to improve outcomes include tailored care for older adults, nutritional support, treatment monitoring, and enhanced MDR-TB management.

Indexed as

curedeathdrug-susceptible tuberculosisfailuremultidrug resistance

Identifiers

PMID40092521
PMCPMC11906029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.